FDMT
4D Molecular Therapeutics, Inc.
Price Chart
Latest Quote
$10.42
+0.76 (+7.87%)
Current Price
| Previous Close | $9.66 |
| Open | $9.82 |
| Day High | $10.89 |
| Day Low | $9.75 |
| Volume | 1,664,440 |
Stock Information
| Shares Outstanding | 52.28M |
| Total Debt | $20.54M |
| Cash Equivalents | $390.89M |
| Revenue | $88.24M |
| Net Income | $-160.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $544.72M |
| EPS (TTM) | $-2.58 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $134.63M |
| Sales | $88.24M |
| Income | $-160.90M |
| Book/sh | $8.64 |
| Cash/sh | $7.48 |
| Employees | 196 |
Financial Ratios
| Quick Ratio | 9.01 |
| Current Ratio | 9.34 |
| Debt/Eq | 4.54 |
Returns & Margins
| ROA | -21.43% |
| ROE | -34.92% |
| Gross Margin | -145.66% |
| Operating Margin | -2416.15% |
| Profit Margin | -182.34% |
Ownership
| Insider Ownership | 3.54% |
| Institutional Ownership | 98.36% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.80 |
| P/S | 6.17 |
| P/B | 1.21 |
Analyst Data
| Recommendation | none |
| Target Price | $28.22 |
Technical Indicators
| SMA20 | $9.19 |
| SMA50 | $9.44 |
| SMA200 | $9.26 |
| RSI | 55.50 |
| ATR | 0.8058 |
| Shares Float | 38.83M |
| Short Float | 26.96% |
| Short Ratio | 16.27 |
| Volatility | 2.76 |
| Rel Volume | 1.86 |
Performance History
| Week | +18.01% |
| Month | +23.02% |
| Quarter | +21.02% |
| 6 Months | +13.14% |
| YTD | +42.35% |
| Year | +154.77% |
| 3 Years | -52.83% |
| 5 Years | -64.40% |
| 10 Years | -74.27% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $10.42 | 1,664,440 |
| 2026-06-18 | $9.66 | 892,200 |
| 2026-06-17 | $9.42 | 962,800 |
| 2026-06-16 | $8.67 | 766,700 |
| 2026-06-15 | $9.22 | 1,064,900 |
| 2026-06-12 | $8.83 | 560,200 |
| 2026-06-11 | $8.84 | 680,300 |
| 2026-06-10 | $8.72 | 623,600 |
| 2026-06-09 | $9.23 | 609,100 |
| 2026-06-08 | $8.64 | 565,100 |
| 2026-06-05 | $8.64 | 644,600 |
| 2026-06-04 | $10.01 | 1,051,800 |
| 2026-06-03 | $9.53 | 949,200 |
| 2026-06-02 | $9.27 | 895,200 |
| 2026-06-01 | $9.71 | 1,075,100 |
| 2026-05-29 | $9.91 | 3,316,700 |
| 2026-05-28 | $8.97 | 279,800 |
| 2026-05-27 | $8.85 | 401,300 |
| 2026-05-26 | $8.71 | 392,900 |
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
đ° Latest News
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
Insider Monkey âĸ 2026-05-20T12:36:07Z
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
MarketBeat âĸ 2026-05-17T00:02:18Z
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St. âĸ 2026-05-11T14:04:12Z
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:14Z
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T12:50:06Z
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
Zacks âĸ 2026-04-10T13:57:00Z
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-03-18T21:25:01Z
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference
MarketBeat âĸ 2026-03-16T10:31:23Z
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk
MarketBeat âĸ 2026-03-16T09:15:35Z
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
Insider Monkey âĸ 2026-02-28T07:21:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 |
| Operating Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 |
| Expenses | ||||
| Total Expenses | $244,756,000 | $187,878,000 | $133,590,000 | $113,161,000 |
| Other Income Expense | $-37,000 | $-77,000 | $-181,000 | $-35,000 |
| Other Non Operating Income Expenses | $-37,000 | $-77,000 | $-181,000 | $-35,000 |
| Net Non Operating Interest Income Expense | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Operating Expense | $244,756,000 | $187,878,000 | $133,590,000 | $113,161,000 |
| General And Administrative Expense | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Interest Income | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Interest Income | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Normalized Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income From Continuing And Discontinued Operation | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Total Operating Income As Reported | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Net Income Common Stockholders | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income Including Noncontrolling Interests | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income Continuous Operations | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Pretax Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Interest Income Non Operating | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Operating Income | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Per Share | ||||
| Diluted EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 |
| Basic EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-151,922,000 | $-181,136,000 | $-107,118,000 | $-106,152,000 |
| Reconciled Depreciation | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| EBITDA (Bullshit earnings) | $-151,922,000 | $-181,136,000 | $-107,118,000 | $-106,152,000 |
| EBIT | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Diluted Average Shares | $57,930,180 | $53,943,741 | $39,130,067 | $32,351,221 |
| Basic Average Shares | $57,930,180 | $53,943,741 | $39,130,067 | $32,351,221 |
| Diluted NI Availto Com Stockholders | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Research And Development | $195,696,000 | $141,299,000 | $97,096,000 | $80,253,000 |
| Selling General And Administration | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
| Other Gand A | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Total Assets | $566,711,000 | $560,384,000 | $339,891,000 | $261,846,000 |
| Total Non Current Assets | $153,577,000 | $125,452,000 | $43,303,000 | $41,335,000 |
| Other Non Current Assets | $9,188,000 | $4,261,000 | $684,000 | $1,080,000 |
| Investmentin Financial Assets | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Current Assets | $413,134,000 | $434,932,000 | $296,588,000 | $220,511,000 |
| Other Current Assets | $10,479,000 | $10,055,000 | $8,356,000 | $6,957,000 |
| Cash Cash Equivalents And Short Term Investments | $402,655,000 | $424,877,000 | $288,232,000 | $213,554,000 |
| Cash And Cash Equivalents | $60,241,000 | $149,336,000 | $249,108,000 | $52,351,000 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $21,413,000 | $24,606,000 | $14,671,000 | $16,124,000 |
| Long Term Debt And Capital Lease Obligation | $15,821,000 | $18,969,000 | $11,522,000 | $13,469,000 |
| Current Debt And Capital Lease Obligation | $5,592,000 | $5,637,000 | $3,149,000 | $2,655,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $61,047,000 | $49,778,000 | $32,062,000 | $30,509,000 |
| Total Non Current Liabilities Net Minority Interest | $17,062,000 | $20,629,000 | $13,111,000 | $14,778,000 |
| Other Non Current Liabilities | $138,000 | $193,000 | $248,000 | $21,000 |
| Derivative Product Liabilities | $358,000 | $410,000 | $369,000 | $212,000 |
| Non Current Deferred Liabilities | $745,000 | $1,057,000 | $972,000 | $1,076,000 |
| Current Liabilities | $43,985,000 | $29,149,000 | $18,951,000 | $15,731,000 |
| Current Deferred Liabilities | $360,000 | $257,000 | $273,000 | $884,000 |
| Payables And Accrued Expenses | $38,033,000 | $23,255,000 | $15,529,000 | $12,192,000 |
| Payables | $11,159,000 | $4,386,000 | $3,515,000 | $3,322,000 |
| Accounts Payable | $11,159,000 | $4,386,000 | $3,515,000 | $3,322,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Total Equity Gross Minority Interest | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Stockholders Equity | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Gains Losses Not Affecting Retained Earnings | $727,000 | $229,000 | $16,000 | $-1,196,000 |
| Other Equity Adjustments | $727,000 | $229,000 | $16,000 | $-1,196,000 |
| Retained Earnings | $-716,304,000 | $-576,195,000 | $-415,327,000 | $-314,490,000 |
| Other | ||||
| Ordinary Shares Number | $57,607,874 | $45,793,942 | $43,075,218 | $32,626,627 |
| Share Issued | $57,607,874 | $45,793,942 | $43,075,218 | $32,626,627 |
| Tangible Book Value | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Invested Capital | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Working Capital | $369,149,000 | $405,783,000 | $277,637,000 | $204,780,000 |
| Capital Lease Obligations | $21,413,000 | $24,606,000 | $14,671,000 | $16,124,000 |
| Total Capitalization | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Additional Paid In Capital | $1,221,235,000 | $1,086,567,000 | $723,136,000 | $547,020,000 |
| Capital Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Common Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $745,000 | $1,057,000 | $972,000 | $1,076,000 |
| Long Term Capital Lease Obligation | $15,821,000 | $18,969,000 | $11,522,000 | $13,469,000 |
| Current Deferred Revenue | $360,000 | $257,000 | $273,000 | $884,000 |
| Current Capital Lease Obligation | $5,592,000 | $5,637,000 | $3,149,000 | $2,655,000 |
| Current Accrued Expenses | $26,874,000 | $18,869,000 | $12,014,000 | $8,870,000 |
| Investments And Advances | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Available For Sale Securities | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Net PPE | $33,010,000 | $40,608,000 | $31,665,000 | $35,347,000 |
| Accumulated Depreciation | $-21,279,000 | $-16,585,000 | $-11,932,000 | $-7,728,000 |
| Gross PPE | $54,289,000 | $57,193,000 | $43,597,000 | $43,075,000 |
| Leases | $18,467,000 | $17,763,000 | $16,902,000 | $16,902,000 |
| Construction In Progress | $0 | $1,182,000 | $550,000 | $476,000 |
| Machinery Furniture Equipment | $17,679,000 | $17,174,000 | $14,606,000 | $12,612,000 |
| Buildings And Improvements | $18,143,000 | $21,074,000 | $11,539,000 | $13,085,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $342,414,000 | $275,541,000 | $39,124,000 | $161,203,000 |
| Other Properties | - | - | $11,539,000 | $13,085,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-109,618,000 | $-138,371,000 | $-78,563,000 | $-98,221,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-109,082,000 | $-134,585,000 | $-75,792,000 | $-86,685,000 |
| Cash Flow From Continuing Operating Activities | $-109,082,000 | $-134,585,000 | $-75,792,000 | $-86,685,000 |
| Operating Gains Losses | $-52,000 | $107,000 | $245,000 | $85,000 |
| Investing Activities | ||||
| Capital Expenditure | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Investing Cash Flow | $-92,973,000 | $-302,437,000 | $115,717,000 | $-17,050,000 |
| Cash Flow From Continuing Investing Activities | $-92,973,000 | $-302,437,000 | $115,717,000 | $-17,050,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Financing Cash Flow | $112,960,000 | $337,250,000 | $156,832,000 | $3,085,000 |
| Cash Flow From Continuing Financing Activities | $112,960,000 | $337,250,000 | $156,832,000 | $3,085,000 |
| Net Common Stock Issuance | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Common Stock Issuance | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Net Other Financing Charges | - | - | - | $-468,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $60,241,000 | $149,336,000 | $249,108,000 | $52,351,000 |
| Beginning Cash Position | $149,336,000 | $249,108,000 | $52,351,000 | $153,001,000 |
| Changes In Cash | $-89,095,000 | $-99,772,000 | $196,757,000 | $-100,650,000 |
| Proceeds From Stock Option Exercised | $2,237,000 | $5,838,000 | $8,488,000 | $3,553,000 |
| Net Investment Purchase And Sale | $-92,437,000 | $-298,651,000 | $118,488,000 | $-5,514,000 |
| Sale Of Investment | $350,384,000 | $169,001,000 | $173,290,000 | $147,799,000 |
| Purchase Of Investment | $-442,821,000 | $-467,652,000 | $-54,802,000 | $-153,313,000 |
| Net PPE Purchase And Sale | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Purchase Of PPE | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Change In Working Capital | $6,172,000 | $537,000 | $630,000 | $-1,336,000 |
| Change In Other Working Capital | $-209,000 | $69,000 | $-715,000 | $-3,130,000 |
| Change In Other Current Liabilities | $-3,193,000 | $-1,651,000 | $-1,453,000 | $-324,000 |
| Change In Other Current Assets | $-4,927,000 | $-3,577,000 | $-70,000 | $-11,000 |
| Change In Payables And Accrued Expense | $14,925,000 | $7,395,000 | $4,267,000 | $847,000 |
| Change In Accrued Expense | $8,152,000 | $6,524,000 | $3,371,000 | $2,485,000 |
| Change In Payable | $6,773,000 | $871,000 | $896,000 | $-1,638,000 |
| Change In Account Payable | $6,773,000 | $871,000 | $896,000 | $-1,638,000 |
| Change In Prepaid Assets | $-424,000 | $-1,699,000 | $-1,399,000 | $1,235,000 |
| Stock Based Compensation | $22,016,000 | $26,116,000 | $19,665,000 | $17,121,000 |
| Amortization Of Securities | $-4,734,000 | $-7,182,000 | $-1,244,000 | $1,059,000 |
| Depreciation Amortization Depletion | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Depreciation And Amortization | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Depreciation | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Gain Loss On Investment Securities | $-52,000 | $107,000 | $245,000 | $85,000 |
| Net Income From Continuing Operations | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Change In Receivables | - | - | $0 | $47,000 |
| Changes In Account Receivables | - | - | $0 | $47,000 |
Fetched: 2026-06-20